The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender

admin

5 years ago

Toni K. Choueiri, MD Director, The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute discusses The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia